Nektar Therapeutics upgraded by Jefferies with a new price target
$NKTR
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded Nektar Therapeutics from Hold to Buy and set a new price target of $2.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/11/2025 | $2.00 | Hold → Buy | Jefferies |
| 3/14/2025 | $6.00 | Perform → Outperform | Oppenheimer |
| 1/8/2025 | $4.00 | Buy | B. Riley Securities |
| 12/10/2024 | $6.50 | Buy | H.C. Wainwright |
| 11/4/2024 | $7.00 | Overweight | Piper Sandler |
| 9/30/2024 | $4.00 | Buy | BTIG Research |
| 6/28/2024 | $2.00 | Buy | Rodman & Renshaw |
| 11/20/2023 | Underweight | JP Morgan |
Jefferies upgraded Nektar Therapeutics from Hold to Buy and set a new price target of $2.00
Oppenheimer upgraded Nektar Therapeutics from Perform to Outperform and set a new price target of $6.00
B. Riley Securities initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $4.00
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We are on track to report topline data in June from the Phase 2 study of rezpegaldesleukin in atopic dermatitis," said Howard W. Robin, President a
SAN FRANCISCO, May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web
SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 20
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We are on track to report topline data in June from the Phase 2 study of rezpegaldesleukin in atopic dermatitis," said Howard W. Robin, President a
SAN FRANCISCO, May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web
SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time – webcast link hereThe fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-pres
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
DEF 14A - NEKTAR THERAPEUTICS (0000906709) (Filer)
PRE 14A - NEKTAR THERAPEUTICS (0000906709) (Filer)
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh
BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and
SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple